[Correspondence] Carfilzomib for relapsed or refractory multiple myeloma

In the second interim analysis of the randomised phase 3 ENDEAVOR study published in The Lancet Oncology, Meletios Dimopoulos and colleagues1 found that, with long-term follow-up, patients with relapsed or refractory multiple myeloma treated with carfilzomib and dexamethasone (median 47 ·6 months [95% CI 42·5-not evaluable]) had significantly longer overall survival than those who were treated with bortezomib and dexamethasone (40·0 months [32·6–42·3]; hazard ratio 0·791 [95% CI 0·648–0·964]). Although the study was done as an open-label study because of the different d osing schedules for the two proteasome inhibitors, baseline clinical and treatment characteristics, including various prognostic factors and subsequent antimyeloma therapies, were generally balanced between groups.
Source: The Lancet Oncology - Category: Cancer & Oncology Authors: Tags: Correspondence Source Type: research